Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
Shares screen as undervalued after prolonged decline.
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.10 | 65.20 | 0.72% |
| CAC 40 | 8,323.28 | 49.44 | 0.60% |
| DAX 40 | 25,014.87 | 293.41 | 1.19% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,386.23 | 16.48 | 0.16% |
| HKSE | 27,027.16 | 467.21 | 1.76% |
| NASDAQ | 23,238.67 | 207.46 | 0.90% |
| Nikkei 225 | 56,363.94 | 2,110.26 | 3.89% |
| NZX 50 Index | 13,416.92 | 29.45 | -0.22% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 8,870.10 | 59.20 | 0.67% |
| SSE Composite Index | 4,123.09 | 57.51 | 1.41% |